Your browser is no longer supported. Please, upgrade your browser.
Settings
WVE [NASD]
Wave Life Sciences Ltd.
Index- P/E- EPS (ttm)-5.05 Insider Own1.50% Shs Outstand38.36M Perf Week10.13%
Market Cap522.19M Forward P/E- EPS next Y-1.64 Insider Trans-14.26% Shs Float21.19M Perf Month5.26%
Income-177.90M PEG- EPS next Q-0.61 Inst Own74.90% Short Float20.67% Perf Quarter15.60%
Sales13.00M P/S40.17 EPS this Y-12.90% Inst Trans-2.79% Short Ratio7.29 Perf Half Y-14.22%
Book/sh2.82 P/B3.80 EPS next Y58.10% ROA-68.60% Target Price- Perf Year34.99%
Cash/sh4.44 P/C2.41 EPS next 5Y- ROE-377.80% 52W Range6.61 - 19.98 Perf YTD36.02%
Dividend- P/FCF- EPS past 5Y- ROI-327.00% 52W High-46.42% Beta0.37
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low61.95% ATR0.69
Employees301 Current Ratio2.40 Sales Q/Q20.70% Oper. Margin- RSI (14)57.89 Volatility7.51% 6.79%
OptionableYes Debt/Eq0.00 EPS Q/Q41.70% Profit Margin- Rel Volume1.24 Prev Close10.03
ShortableYes LT Debt/Eq0.00 EarningsMar 04 BMO Payout- Avg Volume601.02K Price10.70
Recom2.40 SMA202.42% SMA5011.03% SMA2008.73% Volume744,953 Change6.73%
Dec-15-20Resumed H.C. Wainwright Buy $20
Oct-23-20Initiated RBC Capital Mkts Sector Perform $13
Dec-31-19Downgrade SVB Leerink Outperform → Mkt Perform $33 → $10
Nov-01-19Initiated Guggenheim Buy $43
Jul-15-19Initiated Cowen Market Perform
Apr-17-19Reiterated H.C. Wainwright Buy $49 → $33
Aug-07-18Initiated Stifel Buy $56
Jul-23-18Initiated H.C. Wainwright Buy $49
Mar-19-18Reiterated Mizuho Buy $34 → $65
Feb-15-17Initiated H.C. Wainwright Buy $41
Nov-10-16Resumed Leerink Partners Outperform
Dec-07-15Initiated Sun Trust Rbsn Humphrey Buy $26
Dec-07-15Initiated Leerink Partners Outperform $20
Dec-07-15Initiated JMP Securities Mkt Outperform $52
Dec-07-15Initiated Jefferies Buy $28
Feb-23-21 08:00AM  
Feb-16-21 05:00PM  
Feb-08-21 10:11AM  
Jan-12-21 08:47AM  
Jan-11-21 08:00AM  
Dec-02-20 08:00AM  
Nov-12-20 08:11AM  
Nov-10-20 08:00AM  
07:44AM  
Nov-09-20 05:30PM  
08:55AM  
08:14AM  
07:30AM  
06:30AM  
Nov-02-20 12:31PM  
Oct-26-20 04:05PM  
Oct-23-20 10:48AM  
Sep-28-20 04:05PM  
Sep-23-20 10:02AM  
07:00AM  
Sep-22-20 04:19PM  
04:01PM  
Sep-16-20 09:14AM  
Sep-15-20 08:20AM  
07:30AM  
Sep-10-20 04:25PM  
Aug-10-20 09:30PM  
08:45AM  
08:11AM  
07:30AM  
Aug-06-20 08:00AM  
Aug-03-20 12:31PM  
Jul-27-20 04:05PM  
12:31PM  
Jun-24-20 08:46AM  
Jun-18-20 05:14PM  
May-26-20 04:05PM  
May-18-20 07:30AM  
May-11-20 07:01PM  
08:55AM  
07:53AM  
07:30AM  
Apr-29-20 04:05PM  
Apr-23-20 07:01PM  
Apr-22-20 06:35PM  
Mar-24-20 10:38AM  
Mar-02-20 07:55AM  
06:45AM  
Feb-26-20 11:55AM  
Feb-24-20 12:30PM  
Feb-19-20 08:00AM  
Feb-18-20 08:00AM  
Feb-13-20 08:05AM  
Jan-22-20 11:48AM  
Jan-16-20 09:39AM  
Jan-14-20 09:55AM  
Dec-31-19 06:10AM  
Dec-30-19 04:10PM  
07:00AM  
06:24AM  
Dec-24-19 12:18PM  
Dec-23-19 09:52AM  
Dec-16-19 04:09PM  
02:37PM  
09:27AM  
07:00AM  
Dec-11-19 02:21PM  
Dec-06-19 02:23PM  
Nov-14-19 10:02AM  
Nov-06-19 12:15PM  
Nov-05-19 07:15PM  
04:05PM  
Nov-01-19 10:30AM  
Oct-28-19 02:13PM  
Sep-18-19 02:12PM  
Sep-16-19 07:30AM  
Sep-06-19 08:30AM  
Aug-26-19 04:05PM  
Aug-20-19 12:20PM  
Aug-06-19 07:30AM  
Jul-29-19 07:05PM  
04:05PM  
Jul-17-19 03:23PM  
Jul-01-19 09:35AM  
Jun-27-19 08:00AM  
08:00AM  
Jun-12-19 08:00AM  
Jun-06-19 06:10PM  
May-10-19 08:45AM  
07:42AM  
07:30AM  
May-02-19 02:18PM  
May-01-19 10:33AM  
Apr-23-19 12:23PM  
Apr-17-19 11:10AM  
07:48AM  
Apr-16-19 05:17PM  
12:14PM  
07:00AM  
Apr-13-19 09:38AM  
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Francis ChrisSee RemarksFeb 16Sale10.572,69828,51878,462Feb 18 07:26 PM
BOLNO PAULPresident and CEOFeb 16Sale10.5711,205118,437410,976Feb 18 07:18 PM
Panzara Michael A.See RemarksFeb 16Sale10.572,92930,96086,420Feb 18 07:16 PM
Vargeese ChandraChief Technology OfficerFeb 16Sale10.573,14533,24385,412Feb 18 07:14 PM
Moran KyleChief Financial OfficerFeb 16Sale10.571,72218,20269,862Feb 18 07:09 PM
BOLNO PAULPresident and CEOSep 15Option Exercise2.48100,000248,000372,181Sep 17 09:10 PM
BOLNO PAULPresident and CEOSep 15Sale15.00100,0001,500,000272,181Sep 17 09:10 PM
BOLNO PAULPresident and CEOAug 25Option Exercise2.4825,00062,000297,181Aug 27 06:44 PM
BOLNO PAULPresident and CEOAug 25Sale12.0025,000300,000272,181Aug 27 06:44 PM
BOLNO PAULPresident and CEOJul 02Option Exercise2.48100,000248,000372,181Jul 02 08:56 PM
BOLNO PAULPresident and CEOJul 02Sale10.30147,5771,520,276272,181Jul 02 08:56 PM